Rare Genetic Epilepsy Responsive To Marinus's Ganaxolone
Meets Primary Endpoint In Phase III MARIGOLD Study
Executive Summary
Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.
You may also be interested in...
Reviving A Longsuffering Neuro Company: The Marinus Story
Marinus Pharmaceuticals’ CEO spoke candidly to In Vivo about breathing new life into ultra-rare epilepsy disorder drug ganaxolone.
After Years Of Setbacks, Marinus Closes In On Rare Epilepsy Opportunity
After multiple failed attempts to treat rare conditions, Marinus is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion.
Rare Pediatric Disease Voucher Program Gains Temporary Extension From House Committee
US incentive program would gain only four more years, despite calls for a permanent extension.